News
Two patients with MASH share their paths to diagnosis, including the challenges they faced and what it took to find answers.
33m
Study Finds on MSNWeight Loss Showdown: Mounjaro (Tirzepatide) Trounces Wegovy in Head-to-Head TrialIn a nutshell Tirzepatide (Mounjaro) produced 20.2% weight loss compared to semaglutide’s (Wegovy) 13.7% after 72 weeks of ...
Zaina Jasser urges patients and medical practitioners to be cautious of the moral and sociological implications of ...
Tirzepatide slashed weight by 20%, leading researchers to call this a new “golden age” for weight-loss therapies.
Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are tied to a reduction in alcohol intake, according to a research ...
New research being presented at the European Congress on Obesity (ECO25) in Malaga, Spain (11–14 May) and published in the ...
Tirzepatide (trade name Zepbound) promoted greater weight loss in individuals with obesity than did semaglutide (trade name Wegovy) in a clinical trial that compared the safety and efficacy of the ...
The table below is a review of notable updates that occurred in April 2025 for investigational products in development (not an inclusive list). Click on the status to view our full coverage.
News Evidence That GLP-1 Drugs Achieve Weight Loss Primarily by Reducing Fat Mass More Than Muscle. Diabetes and obesity have become pressing health issues worldwide. Glucagon-lik ...
GLP-1 receptor agonists like Ozempic and Wegovy may cut cancer risk beyond controlling blood sugar and weight, offering dual ...
Research has found that weight-loss drugs such as Ozempic may help curb addictive behaviours, such as alcohol addiction. One 2025 study, published in the journal JAMA Psychiatry, found that ...
Landmark research suggests the appetite-suppressing jabs which mimic a hormone that makes us feel full also significantly cut ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results